２０２１年８月３１日、クルクルージュの免疫機能に関する論文が、J-STAGE上で公開されました。
タイトル
Newly Developed Highly Bioavailable Curcumin Formulation, curcuRouge™, Reduces Neutrophil/Lymphocyte Ratio in the Elderly: A Double-Blind, Placebo-Controlled Clinical Trial
著者
Atsuhiro KISHIMOTO, Atsushi IMAIZUMI, Hiromichi WADA, Hajime YAMAKAGE, Noriko SATOH-ASAHARA, Tadashi HASHIMOTO, Koji HASEGAWA
雑誌名
Journal of Nutritional Science and Vitaminology 2021年 67巻 4号 p. 249-252
抄録
Elevated neutrophil/lymphocyte ratio (NLR) has been reported as a sensitive marker for predicting poor prognosis in chronic inflammation-based diseases such as stroke, heart failure, cancers, and diabetes, as well as acute inflammatory diseases such as bacterial and viral infections, including COVID-19. NLR is also known to increase with age and is considered to be an aging marker. We conducted a double-blind, placebo-controlled trial in elderly volunteers to examine the effect of a newly developed, highly bioavailable curcumin formulation (curcuRouge™) on NLR. Both the white blood cell count and the neutrophil rate decreased significantly, and the lymphocyte rate increased significantly from baseline to after curcuRouge™ administration for 4 wk. curcuRouge™ significantly reduced the NLR (p=0.020). On the other hand, in the placebo group, there were no changes in white blood cell count, neutrophil ratio, lymphocyte ratio, or NLR. The present study demonstrates for the first time, in elderly volunteers, that administration of curcuRouge™ significantly reduces NLR, an indicator of prognosis in cardiovascular diseases, cancer, infectious diseases, and aging. Thus, curcuRouge™ might be expected to improve the prognosis of these diseases as well as exhibit anti-aging effects.
試験の概要
試験デザイン：ランダム化プラセボ対照二重盲検並行群間比較試験
対象者： 60歳以上の男女
試験群： クルクルージュ摂取群；1カプセルあたりクルクミン90mgを1日2カプセル
プラセボ群；1日2プラセボカプセル
摂取期間： 4週間
対象者数： 1群あたり20名
主要評価項目：リンパ球の種類と数
好中球／リンパ球比（Neutrophil-Lymphocyte Ratio： NLR）は慢性炎症のマーカーとして知られており、NLRが低いほど健全な免疫状態を保持していると言われています。またNLRは加齢とともに増加することも知られていますが、クルクルージュを28日間摂取することでNLRを0.34有意に低減することが分かりました。一方、プラセボグループでは有意な差は見られませんでした。
Comments